Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Non-Alzheimers Dementia 3 Vascular Dementia
Lancet 386:1698-1706, OBrien, J.T. & Thomas, A., 2015
Update on the Pathophysiology and Management of Idiopathic Intracranial Hypertension
JNNP 83:488-494, Biousse,V.,et al, 2012
Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment
Neurol 70:2024-2035, Winblad,B.,et al, 2008
Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical Features
AJNR 29:1036-1042, Bartynski,W.S., 2008
Natural History of Conservatively Treated Meningiomas
Neurol 63:1133-1134, Herscovici,A.,et al, 2004
Prognosis for Seizure Recurrence in Patients with Newly Diagnosed Neurocysticercosis
Neurol 59:1730-1734,1669, Carpio,A. &Hauser,W.A., 2002
Is the Course of Neurocysticercosis Modified by Treatment with Anthelmintic Agents
Arch Int Med 157:128-129, DelBrutto,O.H., 1997
Medical Treatment of Cysticercosis-Ineffective
Arch Neurol 52:101-102, 1041995., Kramer,L.D., 1995
Medical Treatment of Cysticercosis-Effective
Arch Neurol 52:102-104, DelBrutto,O.H., 1995
Is the Course of Neurocysticercosis Modified by Treatment with Antihelminthic Agents
Arch Int Med 155:1982-1988, Carpio,A.,et al, 1995